The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

While they have been around for some years, ADCs – which pair antibodies with a drug payload designed to boost their efficacy – are gathering momentum in biopharma drug development as early ...

Antibody-drug conjugates or ADCs like Dato-DXd are being considered a disruptive innovation in the pharmaceutical industry as ...

Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the ...

Antibody-drug conjugates (ADCs) can be described as highly targeted biopharmaceutical drugs that integrate monoclonal antibodies specific to surface antigens and highly potent anti-cancer agents ...

Antibody–drug conjugates (ADCs) have emerged as a promising cancer treatment modality, with most of the 15 approved by the US Food and Drug Administration (FDA) reaching the market over the last ...

A first-in-class antibody-drug conjugate (ADC), Elahere, was added to AbbVie’s portfolio earlier this year in February following the acquisition of ImmunoGen for $10.1 billion.

The company’s antibody–drug conjugate (ADC) platform combines cutting edge effector chemistries, payloads, and linkers to enhance the efficacy and safety of ADCs. The key features of the ...

a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as an oral presentation during the plenary session.

Prof. Wenfeng Fang said, "The emergence of ADC drugs is epoch-making. The dual-drug regimen of sac-TMT combined with immunotherapy is leading a new direction in the exploration of first-line ...